Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tocilizumab for Rheumatoid Arthritis: Single-Center Prospective Observational Study
ChiCTR2500104282Phase 4Not yet recruiting
- Sponsor
- First People's Hospital of Lianyungang City
- Start
- Jun 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of tocilizumab in rheumatoid arthritis (RA), sponsored by First People's Hospital of Lianyungang City. Primary endpoint: Percent of ACR20 responders at Week 24. Planned start Jun 2025; status: not yet recruiting.
02
Drugs
tocilizumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on ChiCTR2500104282.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500104282.